Last reviewed · How we verify
NCT02884297: HOPE
HexafluOride, a Contrast Agent for Placenta Echo-angiography
Phase 3 trial testing Contrast agent: SonoVue®. in Pregnancy in 55 participants. Completed in 30 September 2019.
30 September 2019
Quick facts
| Lead sponsor | Centre Hospitalier Régional Metz-Thionville |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 55 |
| Start date | 12 October 2016 |
| Primary completion | 30 September 2019 |
| Estimated completion | 30 September 2019 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Contrast agent: SonoVue®. — full drug profile →
Conditions studied
- Pregnancy — all drugs for Pregnancy →
Sponsor
Centre Hospitalier Régional Metz-Thionville
Who can join
Adults 18 to 65, female only, with Pregnancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to quantify the placental perfusion during the first trimester of pregnancy by 3D Doppler ultrasound angiography without a contrast agent and by ultrasound with a contrast agent: SonoVue®
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02884297
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pregnancy
Currently open trials in the same condition.
- NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07385807 — Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Out · recruiting
- NCT07226492 — Cash Transfers to Pregnant Women With HIV · NA · recruiting
- NCT07435766 — Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy · NA · recruiting
Other Centre Hospitalier Régional Metz-Thionville trials
Trials by the same sponsor.
- NCT07435389 — VENTILATION DURING SPACEFLIGHT (PHASE 2) · NA · not yet recruiting
- NCT07405996 — Referral of Patients With Biological Abnormalities to an Emergency Department · not yet recruiting
- NCT07406022 — Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis. · not yet recruiting
- NCT07515404 — A New Multimodal and Semi-specific Therapeutic Plasmapheresis Concept, a Case Series Study · completed
- NCT07390604 — Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patien · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02884297 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Régional Metz-Thionville
- Last refreshed: 6 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02884297.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing